Arthneeti
FB

Fermenta Biotech Ltd

Q2 FY25Pharmaceuticals & Biotechnology

Fermenta Biotech Ltd Q2 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book

Q2 FY25 investor presentation: what the company reported on revenue, margins and projects.

Price₹478
Market cap₹1.4K Cr
P/E25.5
Updated24 Sept 2026
Read3 min read

Based on Fermenta Biotech Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q2-FY25 Operational Revenue: - Standalone: INR 895 Mn, a 74.5% YoY increase (from INR 513 Mn in Q2-FY24) (Page 9) - Consolidated: INR 950 Mn, a 67.0% YoY increase (from INR 569 Mn in Q2-FY24) (P Quarterly Consolidated Financials (Q2-FY25 vs Q2-FY24): - Operational Revenue: INR 950 Mn, up 67.0% YoY - Operational EBITDA: INR 187 Mn (margin 19.68%), compared to -139 Mn (negative margin

From Fermenta Biotech Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q2-FY25 Operational Revenue:
  • Standalone: INR 895 Mn, a 74.5% YoY increase (from INR 513 Mn in Q2-FY24) (Page 9)
  • Consolidated: INR 950 Mn, a 67.0% YoY increase (from INR 569 Mn in Q2-FY24) (Page 11)
  • Volume Highlights (Page 7):
  • Vitamin D3 for Human Nutrition volumes increased by 62% YoY in Q2-FY25
  • Animal Feed volumes increased by 137% YoY in Q2-FY25
  • Animal Feed average prices were 3 times higher in Q2-FY25 vs Q2-FY24
  • Outlook:

2 more points management made on revenue & sales performance

Profitability & Margins

See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The presentation does not explicitly mention any detailed information on specific capex, capacity expansion, or new plant/project investments, including amounts, status, or timelines. It primarily focuses on financial performance, operational highlights, and strategic developments like the sale of real estate assets (Ceejay House property for INR 400 million) and debt repayment. No other capex or expansion projects are described in the provided content.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided investor presentation for Fermenta Biotech Limited does not mention or report any details regarding order book, order inflow, or pending orders. The presentation focuses on financial performance, operational highlights, product segments, market presence, and other corporate updates, but does not include any specific information about order status or order backlog.

Fermenta Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹122 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Fermenta Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt Ltd (Q2 FY25)

    Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key investor presentation takeaways from Wockhardt

  • Anuh Pharma Ltd (Q2 FY25)

    Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key investor presentation takeaways from Anuh Pharma Ltd's Q2 FY25 investor presentation — and how it ranks against sec

  • Themis Medicare Ltd (Q2 FY25)

    117.01 Cr, up 11.67% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q2 FY25 investor presentation — and how it ranks against sector

  • Lincoln Pharmaceuticals Ltd (Q2 FY25)

    EBITDA**: ₹1,234 crore, up 15% YoY . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY25 investor presentation — and how it ranks aga

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Fermenta Biotech Ltd Q2 FY25 results?

Q2-FY25 Operational Revenue: - Standalone: INR 895 Mn, a 74.5% YoY increase (from INR 513 Mn in Q2-FY24) (Page 9) - Consolidated: INR 950 Mn, a 67.0% YoY increase (from INR 569 Mn in Q2-FY24) (P Quarterly Consolidated Financials (Q2-FY25 vs Q2-FY24): - Operational Revenue: INR 950 Mn, up 67.0% YoY - Operational EBITDA: INR 187 Mn (margin 19.68%), compared to -139 Mn (negative margin

What is Fermenta Biotech Ltd share price analysis?

Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.

Is Fermenta Biotech Ltd planning capital expenditure?

The presentation does not explicitly mention any detailed information on specific capex, capacity expansion, or new plant/project investments, including amounts, status, or timelines.

Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.